IP Library Granted Patent US 12,173,323
Granted Patent B2
US 12,173,323 · App. 17/573,552 · Granted Dec 24, 2024

Methods of using PDX1-positive pancreatic endoderm cells and endocrine precursor cells

Inventors: Kevin A. D'Amour (San Diego, CA); Anne Bang (San Diego, CA); Emmanuel E. Baetge (Encinitas, CA)
Assignee: ViaCyte, Inc.
C12N5/0676A61K35/39C12N5/0678C12N2500/38C12N2501/10C12N2501/105C12N2501/115C12N2501/119C12N2501/12C12N2501/15C12N2501/16C12N2501/33C12N2501/335C12N2501/385C12N2501/41C12N2501/415C12N2501/42C12N2501/58C12N2501/734C12N2501/999C12N2506/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,173,323
App. No.
17/573,552
Granted
Dec 24, 2024
Kind
B2
Abstract

Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations.

Claims (15)

1. A method of producing insulin in a mammalian subject, comprising:

transplanting an in vitro culture comprising pancreatic and duodenal homeobox 1 (PDX1)-positive pancreatic endoderm cells and endocrine precursor cells into the mammalian subject, wherein the PDX1-positive pancreatic endoderm cells and endocrine precursor cells mature into cells that secrete insulin in response to glucose stimulation,

thereby producing insulin in the mammalian subject.

2. The method of claim 1 , wherein the endocrine precursor cells express neurogenin 3 (NGN3).

3. The method of claim 1 , wherein the endocrine precursor cells express paired box 4 (PAX4).

4. The method of claim 1 , wherein the endocrine precursor cells express NK2 homeobox 2 (NKX2.2).

5. The method of claim 1 , wherein the PDX1-positive pancreatic endoderm cells co-express pancreas associated transcription factor 1a (PTF1A).

6. The method of claim 1 , wherein the PDX1-positive pancreatic endoderm cells co-express NK6 homeobox 1 (NKX6.1).

7. The method of claim 1 , wherein the cells that secrete insulin form islet-like cell clusters.

8. The method of claim 7 , wherein the islet-like cell clusters comprise singly positive insulin cells.

9. The method of claim 7 , wherein the islet-like cell clusters express ghrelin, insulin, somatostatin, pancreatic polypeptide, or glucagon.

10. The method of claim 1 , further comprising measuring C-peptide levels in a sample obtained from the mammalian subject.

11. The method of claim 10 , wherein the levels of C-peptide increases in the mammalian subject over time.

12. The method of claim 1 , wherein the mammalian subject is a human subject.

13. The method of claim 12 , wherein the human subject has a condition which limits the ability of the subject to produce sufficient levels of insulin in response to physiologically high blood glucose concentrations.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2022
From: D'AMOUR, KEVIN A; BANG, ANNE; BAETGE, EMMANUEL E
To: CYTHERA, INC.
Reel/Frame 058971/0256 →
MERGER AND CHANGE OF NAME Recorded Feb 10, 2022
From: CYTHERA, INC.; VIACYTE, INC.
To: VIACYTE, INC.
Reel/Frame 059002/0201 →
Continuity (9)
Division 16445124 · Jun 18, 2019
Continuation 15173316 · Jun 3, 2016
Continuation 14072491 · Nov 5, 2013
Continuation 13275274 · Oct 17, 2011
Division 11681687 · Mar 2, 2007
Provisional Application 60852878 · Oct 18, 2006
Provisional Application 60833633 · Jul 26, 2006
Provisional Application 60778649 · Mar 2, 2006
Related Publication 20220135948A1 · May 5, 2022